Pathologic complete response following low-dose radiation for advanced oral cavity cancer in a patient with human immunodeficiency virus by Amy B. Leming, Andrea L. Johnston, Greg A. Krempl, Evan J. Fowle, Daniel J. Morton, Christina E. Henson

“…Abstract Background Advanced squamous cell carcinoma (SCCa) of the oral cavity is often not amenable to curative-intent therapy due to tumor location, tumor size, or comorbidities. …”
Get full text

Metastatic Status and Dissection Effect of Regional/Extraregional Lymph Nodes in Japanese Patients with Squamous Cell Carcinoma of the Anal Canal: A Multicenter Retrospective Cohor... by Takayuki Torigoe, Keiji Hirata, Kazutaka Yamada, Yoichi Ajioka, Kenichi Sugihara

“…Objectives: Squamous cell carcinoma of the anal canal (SCCA) is a rare condition. Standard treatment includes chemoradiotherapy, with surgical treatment reserved for limited cases. …”
Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

“…The response rates in each cancer cohort were undifferentiated pleomorphic sarcoma 15% (n = 3/20; 95% CI 3–38%), salivary carcinoma 20% (n = 4/20; 95% CI: 6–44%), CUP 17% (n = 3/18; 95% CI 4–41%), SCCA 10% (n = 2/20; 95% CI 12–32%) and CCCO 21% (n = 8/39; 95% CI 9–37%). …”
Get full text